These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 2242261)

  • 21. Natural killer cells in children with malignant solid tumors. Effect of recombinant interferon-alpha and interleukin-2 on natural killer cell function against tumor cell lines.
    Alvarado CS; Findley HW; Chan WC; Hnath RS; Abdel-Mageed A; Pais RC; Kutner MH; Ragab AH
    Cancer; 1989 Jan; 63(1):83-9. PubMed ID: 2783377
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antitumor activities of subsets of human IL-2-activated natural killer cells in solid tissues.
    Vujanovic NL; Yasumura S; Hirabayashi H; Lin WC; Watkins S; Herberman RB; Whiteside TL
    J Immunol; 1995 Jan; 154(1):281-9. PubMed ID: 7995947
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells. A phase II clinical trial.
    Fisher RI; Coltman CA; Doroshow JH; Rayner AA; Hawkins MJ; Mier JW; Wiernik P; McMannis JD; Weiss GR; Margolin KA
    Ann Intern Med; 1988 Apr; 108(4):518-23. PubMed ID: 3258138
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Responses of killer cells in head and neck cancer patients.
    Fujieda S; Saito H; Hoshino T
    Eur Arch Otorhinolaryngol; 1990; 247(3):176-81. PubMed ID: 2350510
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A pilot study of intralymphatic interleukin-2. I. Cytotoxic and surface marker changes of peripheral blood lymphocytes.
    Shau H; Isacescu V; Ibayashi Y; Tokuda Y; Golub SH; Fahey JL; Sarna GP
    J Biol Response Mod; 1990 Feb; 9(1):71-80. PubMed ID: 2319261
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Changes in immunological parameters during interleukin 2 and interferon 2 alpha treatment of recurrent renal cell carcinoma and malignant melanoma.
    Maxwell W; McDevitt J; Reid I; Sharpe I; Feighery C; Tanner WA; Emmons R; Monson JR
    Eur J Surg Oncol; 1993 Jun; 19(3):265-72. PubMed ID: 8314385
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pilot study of interleukin-2 and lymphokine-activated killer cells combined with immunomodulatory doses of chemotherapy and sequenced with interferon alfa-2a in patients with metastatic melanoma and renal cell carcinoma.
    Sznol M; Clark JW; Smith JW; Steis RG; Urba WJ; Rubinstein LV; VanderMolen LA; Janik J; Sharfman WH; Fenton RG
    J Natl Cancer Inst; 1992 Jun; 84(12):929-37. PubMed ID: 1629914
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Defective natural immunity: an early manifestation of human immunodeficiency virus infection.
    Ullum H; Gøtzsche PC; Victor J; Dickmeiss E; Skinhøj P; Pedersen BK
    J Exp Med; 1995 Sep; 182(3):789-99. PubMed ID: 7650485
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Limiting dilution analysis of lymphokine-activated killer cell precursor frequencies in peripheral blood lymphocytes of cancer patients receiving interleukin-2 therapy.
    Albertini MR; Oettel KR; Weil-Hillman G; Lindstrom MJ; Schell K; Hank JA; Sondel PM
    J Biol Response Mod; 1990 Oct; 9(5):456-62. PubMed ID: 2254758
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Renal cell carcinoma: treatment with recombinant interleukin-2 plus beta-interferon.
    Krigel RL; Padavic-Shaller KA; Rudolph AR; Konrad M; Bradley EC; Comis RL
    J Clin Oncol; 1990 Mar; 8(3):460-7. PubMed ID: 2407809
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intracellular calcium changes associated with in vitro lymphokine-activated killer and natural killer cell cytotoxicity.
    Burkey BB; Omann GM; Wolf GT
    Arch Otolaryngol Head Neck Surg; 1991 Nov; 117(11):1281-6. PubMed ID: 1747234
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of anti-CD3 antibody on the generation of interleukin-2-activated lymphocytes from tumor tissues of gastrointestinal cancer.
    Ohta T; Kikuchi H; Ogata H; Iwata K; Yoshida K; Katayama K; Watanabe H
    Cancer; 1992 Aug; 70(4):741-8. PubMed ID: 1386555
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recombinant interleukin-2 and lymphokine-activated killer cell treatment of advanced bladder cancer: clinical results and immunological effects.
    Hermann GG; Geertsen PF; von der Maase H; Steven K; Andersen C; Hald T; Zeuthen J
    Cancer Res; 1992 Feb; 52(3):726-33. PubMed ID: 1732060
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Natural killer cell activity in tumor-draining lymph nodes: investigations in patients with malignant melanoma and head and neck cancer.
    Micksche M; Vinzenz K; Kokoschka EM; Kokoschka R
    Nat Immun Cell Growth Regul; 1985; 4(6):315-27. PubMed ID: 4088287
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Functional and phenotypic analysis of lymphocytes in head and neck cancer.
    Snyderman CH; Heo DS; Johnson JT; D'Amico F; Barnes L; Whiteside TL
    Arch Otolaryngol Head Neck Surg; 1991 Aug; 117(8):899-905. PubMed ID: 1832546
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adoptive immunotherapy of malignant diseases with IL-2-activated lymphocytes.
    Kimoto Y; Taguchi T
    Biken J; 1987 Jun; 30(2):29-38. PubMed ID: 3501954
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Experimental approach to immunotherapy in head and neck malignant tumors--antitumor efficacy by lymphokine activated human peripheral blood lymphocytes].
    Takeda T
    Nihon Jibiinkoka Gakkai Kaiho; 1986 Jun; 89(6):744-53. PubMed ID: 3489826
    [No Abstract]   [Full Text] [Related]  

  • 38. Phase I evaluation of combination therapy with interleukin 2 and gamma-interferon.
    Weiner LM; Padavic-Shaller K; Kitson J; Watts P; Krigel RL; Litwin S
    Cancer Res; 1991 Aug; 51(15):3910-8. PubMed ID: 1906779
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effect of anti-CD3 on the induction of non-MHC restricted cytolytic activity.
    Watanabe H; Narumi K; Stewart CC; Arbuck SG; Foon KA; Goldrosen MH
    Anticancer Res; 1992; 12(6B):1925-33. PubMed ID: 1295440
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Modulation of intestinal immune reactivity by interleukin 2. Phenotypic and functional analysis of lymphokine-activated killer cells from human intestinal mucosa.
    Fiocchi C; Youngman KR; Yen-Lieberman B; Tubbs RR
    Dig Dis Sci; 1988 Oct; 33(10):1305-15. PubMed ID: 3139381
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.